Michael L Gatza
Overview
Explore the profile of Michael L Gatza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed M, Ivan C, Aslan B, et al.
EBioMedicine
. 2024 Dec;
111():105486.
PMID: 39637523
No abstract available.
2.
Khanna P, Mehta R, Mehta G, Bhatt V, Guo J, Gatza M
bioRxiv
. 2023 Sep;
PMID: 37745600
Tumor cells rely on increased glycolytic capacity to promote cell growth and progression. While glycolysis is known to be upregulated in the majority of triple negative (TNBC) or basal-like subtype...
3.
Khella C, Franciosa L, Rodirguez-Rodriguez L, Rajkarnikar R, Mythreye K, Gatza M
Mol Cancer Res
. 2023 Jun;
21(10):1037-1049.
PMID: 37342066
Implications: Collectively, these studies establish that HCK acts as an oncogenic driver of HGSOC through aberrant activation of CD44 and NOTCH3 signaling and identifies this network as a potential therapeutic...
4.
Hussein S, Khanna P, Yunus N, Gatza M
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638293
Metabolic reprogramming enables cancer cells to adapt to the changing microenvironment in order to maintain metabolic energy and to provide the necessary biological macromolecules required for cell growth and tumor...
5.
Jariwala N, Mehta G, Bhatt V, Hussein S, Parker K, Yunus N, et al.
NAR Cancer
. 2021 Sep;
3(3):zcab035.
PMID: 34514415
Chromosome 11q13-14 amplification is a defining feature of high-risk hormone receptor-positive (HR+) breast cancer; however, the mechanism(s) by which this amplicon contributes to breast tumorigenesis remains unclear. In the current...
6.
Tong K, Kothari O, Haro K, Panda A, Bandari M, Carrick J, et al.
Oncogene
. 2021 Aug;
40(41):6034-6048.
PMID: 34453124
BRAF-driven colorectal cancer is among the poorest prognosis subtypes of colon cancer. Previous studies suggest that BRAF-mutant serrated cancers frequently exhibit Microsatellite Instability (MSI) and elevated levels of WNT signaling....
7.
Angus S, Stuhlmiller T, Mehta G, Bevill S, Goulet D, Olivares-Quintero J, et al.
NPJ Breast Cancer
. 2021 May;
7(1):51.
PMID: 33980863
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2...
8.
Mehta G, Angus S, Khella C, Tong K, Khanna P, Dixon S, et al.
NPJ Breast Cancer
. 2021 Apr;
7(1):40.
PMID: 33837205
Dysregulation of PI3K/Akt signaling is a dominant feature in basal-like or triple-negative breast cancers (TNBC). However, the mechanisms regulating this pathway are largely unknown in this subset of aggressive tumors....
9.
Khella C, Mehta G, Mehta R, Gatza M
J Pers Med
. 2021 Mar;
11(2).
PMID: 33669749
The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes...
10.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed M, Ivan C, Aslan B, et al.
EBioMedicine
. 2020 Jan;
52:102630.
PMID: 31972470
No abstract available.